Drug Resistance Start-Ups: Is Resistance Futile?
This article was originally published in Start Up
Executive Summary
Overcoming drug resistance is a key goal of development--but will anyone fund it?
You may also be interested in...
Eyeing the Hospital Market for Infectious Disease Diagnostics
Hospital-based diagnostics are a tough sell to VCs, partly because big companies dominate the central lab. The area of infectious disease is even more challenging because low-cost culture methods are difficult to displace and novel high-value biomarker content is rare. MRSA screening may be one area where the right factors are coming together to form an opportunity. In some other cases, the same attributes that make rapid tests appealing outside the hospital could help bring them inside.
Eyeing the Hospital Market for Infectious Disease Diagnostics
Hospital-based diagnostics are a tough sell to VCs, partly because big companies dominate the central lab. The area of infectious disease is even more challenging because low-cost culture methods are difficult to displace and novel high-value biomarker content is rare. MRSA screening may be one area where the right factors are coming together to form an opportunity. In some other cases, the same attributes that make rapid tests appealing outside the hospital could help bring them inside.
PhageTech Inc.
PhageTech is mining the genome of phage virus, which infect bacteria, for targets with which to create a new generation of antibiotics.